GLP-1 During Ramadan: Fasting & Dosing Guide

Can you keep taking a GLP-1 — Ozempic, Wegovy, Mounjaro, Zepbound, or oral Rybelsus — while fasting for Ramadan? For most people the answer is yes, with planning, and the medical reasoning is favorable. GLP-1 drugs lower blood sugar in a glucose-dependent way: they nudge the body to release insulin mainly when glucose is high, so on their own they carry a low intrinsic risk of hypoglycemia. A 2025 systematic review and meta-analysis of people with type 2 diabetes fasting during Ramadan found GLP-1 users had a 62% lower risk of documented symptomatic hypoglycemia than those on other glucose-lowering medications (risk ratio 0.38), with greater blood-sugar and weight reduction (Kamrul-Hasan 2025 ^[2]). That makes GLP-1s relatively Ramadan-friendly compared with sulfonylureas and insulin, which the IDF-DAR guidelines say usually need dose reduction during the fast (Hassanein 2022 ^[1]). The catches are practical: weekly-injection timing, the empty-stomach rule for oral semaglutide, and guarding against dehydration when appetite drops. See also our guides to missed-dose rules by drug and how long each GLP-1 stays in your system.

The honest summary

• GLP-1s are generally compatible with Ramadan fasting. Limited but consistent evidence finds them safe for type 2 diabetes during Ramadan, with modest benefits in blood-sugar control and weight loss (Kamrul-Hasan 2025^[2]).
• Low hypoglycemia risk is the key advantage. Because GLP-1s act glucose-dependently, they rarely cause lows on their own — meta-analysis hypoglycemia risk was 62% lower than other agents during Ramadan (RR 0.38; Kamrul-Hasan 2025^[2]). That is the opposite of sulfonylureas and insulin, which the IDF-DAR guidelines recommend reducing during the fast (Hassanein 2022^[1]).
• Weekly injections are flexible. Ozempic, Wegovy, Mounjaro, and Zepbound are dosed once weekly, so the daily fasting window does not change the schedule — pick a consistent day and keep it.
• Oral semaglutide (Rybelsus) needs careful timing. It must be taken on an empty stomach with a small sip of water, then nothing by mouth for 30 minutes — which during Ramadan means taking it at the pre-dawn meal (suhoor) before eating, or with the same rule at the evening meal (Hassanein 2025^[4]).
• Hydration and nutrition matter more, not less. GLP-1s blunt appetite, so a smaller suhoor/iftar plus the long fast can compound the drug's GI effects and dehydration risk. Plan deliberate fluids and balanced meals in the eating window.
• Coordinate with your prescriber before Ramadan — especially if you also take insulin or a sulfonylurea, where dose adjustment is usually needed (Hassanein 2022^[1]).

Why GLP-1s are relatively Ramadan-friendly

Fasting for Ramadan is one of the five pillars of Islam and obligatory for healthy adult Muslims; people with diabetes may be exempt, but many choose to fast anyway, so they need sound guidance (Hassanein 2022^[1]). The single biggest medical risk of fasting with diabetes is hypoglycemia — and this is exactly where GLP-1 receptor agonists shine. Unlike sulfonylureas (which force insulin out regardless of blood sugar) or injected insulin, GLP-1s stimulate insulin and suppress glucagon in a glucose-dependent manner: their effect fades as blood sugar falls toward normal, so they seldom drive levels into the low range by themselves.

The clinical data bear this out. A 2025 systematic review and meta-analysis (Kamrul-Hasan 2025^[2], World Journal of Methodology) pooled four studies — three randomized trials plus one observational study, 754 people with type 2 diabetes fasting during Ramadan. The GLP-1 group had a 62% lower risk of documented symptomatic hypoglycemia (risk ratio 0.38, 95% CI 0.16–0.88), a greater drop in HbA1c (mean difference −0.31%), and about 2 kg more weight loss than the comparison group, with overall serious adverse events comparable between groups. A separate real-world study of tirzepatide (a dual GIP/GLP-1 agonist) in 109 fasting patients in Bangladesh reported a 1.1-percentage-point HbA1c fall and 5.3 kg average weight loss with no hypoglycemia reported over the month (Rahman 2026^[3]). The trade-off, in both analyses, is gastrointestinal: nausea and vomiting are more common on GLP-1s.

Timing weekly injections during Ramadan

The once-weekly GLP-1s — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) — are the easy case. Because semaglutide's half-life is roughly a week and tirzepatide's about five days, the drug level barely moves between one daily fast and the next; the medication is working steadily across all 24 hours regardless of when you eat. So the daily Ramadan schedule does not change weekly dosing. Keep your usual injection day, and you can give the shot at any time of day, with or without food — fasting does not break the injection, and a subcutaneous injection of medication is generally not considered to invalidate the fast by most scholarly opinions (confirm with your own religious guidance). If you want to move your injection day to line up better with Ramadan, the FDA labels allow shifting the day as long as the last two doses were given at least 48–72 hours apart — see our missed-dose and day-switching guide and the half-life explainer for the exact rules.

Oral semaglutide (Rybelsus): the empty-stomach rule

Daily oral semaglutide is the one that needs real planning. To be absorbed, it must be taken on an empty stomach with no more than about 120 mL (4 oz) of plain water, followed by no food, drink, or other oral medication for at least 30 minutes (Hassanein 2025^[4]). During Ramadan, the natural fit is the pre-dawn meal (suhoor): take the tablet with a small sip of water as soon as you wake, then wait 30 minutes before eating and drinking the rest of suhoor. The same empty-stomach window can instead be built around the evening meal (iftar) if that suits your routine better. The O-SEMA-FAST study followed 257 people with type 2 diabetes on oral semaglutide through Ramadan and found that most (about 68%) still managed to follow the dosing instructions on the great majority of days, with meaningful HbA1c and weight reductions — and adherent patients did better than non-adherent ones (Hassanein 2025^[4]). The lesson: oral semaglutide can work well during Ramadan, but only if you protect that 30-minute empty-stomach window. The same fasted-stomach principle applies to the investigational oral GLP-1 orforglipron, though it is not yet a marketed product.

Appetite, hydration, and GI side effects

GLP-1s work partly by slowing the stomach and dialing down appetite. During Ramadan that can backfire in a specific way: if the drug suppresses your hunger at suhoor and iftar, you may eat and drink too little in the narrow eating window, which compounds the dehydration that already comes with a long daytime fast. Add the GLP-1's tendency toward nausea and reduced fluid intake, and the risk is volume depletion. Be deliberate about fluids across the non-fasting hours (water between iftar and suhoor, not just at meals), and aim for balanced, protein-containing meals rather than a single large iftar that may worsen nausea or reflux on a slowed stomach. Dehydration also matters for kidney health — see our note on the early eGFR/creatinine dip on GLP-1s, which can be aggravated by fluid loss.

When to talk to your prescriber

• Before Ramadan, ideally weeks ahead. The IDF-DAR framework recommends a pre-Ramadan risk assessment and education for everyone with diabetes who plans to fast (Hassanein 2022^[1]).
• If you also take insulin or a sulfonylurea. These are the drugs that drive fasting hypoglycemia and usually need dose reduction and re-timing — the GLP-1 itself rarely does (Hassanein 2022^[1]).
• If you are newly starting or up-titrating a GLP-1. The first weeks bring the most nausea; starting a dose increase right before Ramadan may make the fast harder to tolerate.
• If you have other conditions — kidney disease, recurrent severe hypoglycemia, pregnancy, or a history of pancreatitis — for which IDF-DAR places you in a higher fasting-risk category that warrants individualized advice.

Bottom line

GLP-1 receptor agonists are generally compatible with Ramadan fasting and, because they lower blood sugar glucose-dependently, carry a lower hypoglycemia risk than sulfonylureas or insulin — in a 2025 meta-analysis the risk of symptomatic lows was 62% lower than other agents (Kamrul-Hasan 2025^[2]; Hassanein 2022^[1]). Weekly injections (Ozempic, Wegovy, Mounjaro, Zepbound) need no schedule change because their week-long action spans the fast; oral semaglutide (Rybelsus) needs its empty-stomach, 30-minute window protected, usually at suhoor (Hassanein 2025^[4]). The real homework is hydration, balanced meals, and — if you also take insulin or a sulfonylurea — a pre-Ramadan dose plan agreed with your clinician. Fasting is a personal decision shaped by both medical and religious guidance; this article is general education, not individualized medical advice.

This article is educational and is not medical or religious advice. Every clinical claim above is sourced to a peer-reviewed guideline, randomized-trial analysis, or observational study indexed in PubMed, verified against the live PubMed database before publication. The evidence base for GLP-1s specifically during Ramadan is still limited — guideline guidance plus a small meta-analysis and individual studies — so coordinate decisions with your own clinician and religious guidance.